Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
AI Summary:
The phase 3 TALAPRO-2 study investigated combining talazoparib with enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations. The primary endpoint, radiographic progression-free survival, was met, and overall survival is immature but favors talazoparib.AI Topics:
Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase. This association provides a rationale for their co-inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC), an area of unmet medical need. The phase 3 TALAPRO-2 study investigated combining the poly(ADP-ribose) polymerase inhibitor talazoparib with enzalutamide versus enzalutamide alone as first-line treatment of mCRPC. Patients were prospectively assessed for tumor alterations in DNA damage response genes involved in homologous recombination repair (HRR). Two cohorts were enrolled sequentially: an all-comers cohort that was enrolled first (cohort 1; N = 805 (169 were HRR-deficient)), followed by an HRR-deficient-only cohort (cohort 2; N = 230). We present results from the alpha-controlled primary analysis for the combined HRR-deficient population (N = 399). Patients were randomized in a 1:1 ratio to talazoparib or placebo, plus enzalutamide. The primary endpoint, radiographic progression-free survival, was met (median not reached at the time of the analysis for the talazoparib group versus 13.8 months for the placebo group; hazard ratio, 0.45; 95% confidence interval, 0.33 to 0.61; P < 0.0001). Data for overall survival, a key secondary endpoint, are immature but favor talazoparib (hazard ratio, 0.69; 95% confidence interval, 0.46 to 1.03; P = 0.07). Common adverse events in the talazoparib group were anemia, fatigue and neutropenia. Combining talazoparib with enzalutamide significantly improved radiographic progression-free survival in patients with mCRPC harboring HRR gene alterations, supporting talazoparib plus enzalutamide as a potential first-line treatment for these patients.
Fizazi, Karim
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listAzad, Arun A.
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listMatsubara, Nobuaki
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listCarles, Joan
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listFay, Andre P.
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listDe Giorgi, Ugo
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listJoung, Jae Young
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listFong, Peter C. C.
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listVoog, Eric
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listJones, Robert
Author
Elyan, Benjamin M.P. and Tan, Beatrix and Lambourg, Emilie and McAllister, David A. and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. and Bell, Samira (2025) Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis. Clinical Kidney Journal, 18 (5): sfaf084. ISSN 2048-8505
Elyan, Benjamin M.P. and Sullivan, Michael K. and Hedley, James and De La Mata, Nicole and Webster, Angela C. and Venugopal, Balaji and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2: 57. ISSN 2731-9377
Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049
See full publications listShore, Neal D.
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listDunshee, Curtis
Author
Zschäbitz, Stefanie
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listOldenburg, Jan
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listYe, Dingwei
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listLin, Xun
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listHealy, Cynthia G.
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listDi Santo, Nicola
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listLaird, A. Douglas
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listZohren, Fabian
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listAgarwal, Neeraj
Author
Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956
See full publications listAvailable under License Creative Commons Attribution.
Download (6MB) | Preview
 |